JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266500

Human UFL1 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UFL1 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 5 bp deletion in exon 2 and 7 bp deletion in exon 2.

View Alternative Names

E3 UFM1-protein ligase 1, KIAA0776, LZAP-binding protein, Maxer, NLBP, RCAD, UFL1_HUMAN, UFM1 specific ligase 1

3 Images
Sanger Sequencing - Human UFL1 knockout HEK-293T cell line (AB266500)
  • Sanger seq

Unknown

Sanger Sequencing - Human UFL1 knockout HEK-293T cell line (AB266500)

Allele-1 : 7 bp deletion in exon2

Sanger Sequencing - Human UFL1 knockout HEK-293T cell line (AB266500)
  • Sanger seq

Unknown

Sanger Sequencing - Human UFL1 knockout HEK-293T cell line (AB266500)

Allele-2 : 5 bp deletion in exon 2.

Sanger Sequencing - Human UFL1 knockout HEK-293T cell line (AB266500)
  • Sanger seq

Unknown

Sanger Sequencing - Human UFL1 knockout HEK-293T cell line (AB266500)

Allele-3 : 2 bp deletion in exon 2.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 5 bp deletion in exon 2 and 7 bp deletion in exon 2

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266500-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266500 Human UFL1 knockout HEK-293T cell line", "number":"AB266500-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266500-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266500 Human UFL1 knockout HEK-293T cell line", "number":"AB266500-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UFL1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UFL1 also known as E3 ubiquitin-protein ligase UFL1 is a protein involved in the post-translational modification process called ufmylation. This protein has a molecular mass of approximately 34 kDa and facilitates the attachment of the ubiquitin-fold modifier 1 (UFM1) to target proteins. UFL1 is widely expressed in various tissues including the liver heart and kidney. It forms part of a complex that includes UFM1 UBA5 and UFC1 which are all essential for its function.
Biological function summary

UFL1 regulates proteins' stability and activity by ufmylation in the endoplasmic reticulum (ER) stress response. This protein modifies select substrates enhancing their role in maintaining cellular homeostasis under stress conditions. UFL1 works closely with UFM1 and is part of a complex that targets specific proteins indicating its role in maintaining proper cellular conditions during ER stress. This modification mechanism is important for cells to adapt to changing environments and sustain normal function.

Pathways

UFL1 plays a role in the ER stress response and protein folding pathways. It operates alongside other proteins including UFM1 which is critical in these processes. UFL1 modulates pathways linked with cellular responses to stress and survival. It interacts with proteins like CDK5 suggesting a role in cellular processes that require precise regulation during stress conditions. Such interactions further integrate UFL1 into overarching cellular survival strategies.

UFL1 has implications in cancer and neurodegenerative diseases. Dysregulation of ufmylation where UFL1 is an important player shows links to tumor progression and survival mechanisms in cancer. UFL1 is also connected to pathological protein aggregation relevant in neurodegenerative diseases. Its interaction with proteins involved in ER stress response suggests a relationship to these conditions. Understanding UFL1's function in these diseases is important for identifying therapeutic targets.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com